Horizon Therapeutics

Horizon Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States. The company's lead product base includes Krystexxa, Duexis and Rayos.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Horizon Therapeutics balance sheet

Report period2018 2019 2020 2021 2022Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Horizon Therapeutics cash flows

Report period2018 2019 2020 2021 2022Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Horizon Therapeutics multipliers

Report period2018 2019 2020 2021 2022Q2 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Horizon Therapeutics profitability

Report period2018 2019 2020 2021 2022Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Horizon Therapeutics assets
Horizon Therapeutics cash flows

Horizon Therapeutics dividend policy

The company doesn't provide dividend.
Horizon Therapeutics news
12.12.2022
Amgen is buying Horizon Therapeutics for $27.8 billion, or $116.5 per share. Closing date of the deal will be announced in the first half of 2023, after receiving all necessary regulatory approvals.
Source: {source} pictogram ir.horizontherapeutics.com
Pictogram next
04.05.2022
Horizon Therapeutics' GAAP net income for 3 months of 2022 was $204.261 million, compared to a loss of $123.351 million in the previous year. Revenue increased 2.6 times to $885.245 million from $342.406 million a year earlier.
Source: {source} pictogram ir.horizontherapeutics.com
Pictogram next
02.05.2022
Horizon Therapeutics has received approval from the European Commission for UPLIZNA. The drug is used to treat adults with neuromyelitic optic spectrum disorder.
Source: {source} pictogram ir.horizontherapeutics.com
Pictogram next
01.03.2022
Horizon Therapeutics' GAAP net income for 2021 was $534.491 million, up 37.1% from $389.796 million in the previous year. Revenue increased 46.6% to $3.226 billion, compared to $2.2 billion a year earlier.
Source: {source} pictogram ir.horizontherapeutics.com
Pictogram next
All Horizon Therapeutics news
General information
Company nameHorizon Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressCONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Mailing addressCONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Websiteir.horizontherapeutics.com
Information disclosurewww.sec.gov